MedPath

Tango Therapeutics

Tango Therapeutics logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Public
Established
2017-01-01
Employees
140
Market Cap
$1.2B
Website
http://www.tangotx.com
Introduction

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Phase 1
Terminated
Conditions
Pancreas Cancer
HRD Positive Advanced Ovarian Cancer
Breast Cancer
Ovarian Cancer
BRCA1 Mutation
Prostate Cancer
BRCA-Mutated Ovarian Carcinoma
BRCA-Associated Breast Carcinoma
Interventions
Drug: TNG348
Drug: Olaparib
First Posted Date
2023-10-03
Last Posted Date
2024-08-13
Lead Sponsor
Tango Therapeutics, Inc.
Target Recruit Count
7
Registration Number
NCT06065059
Locations
๐Ÿ‡บ๐Ÿ‡ธ

New York University Langone Health, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mid Florida Cancer Centers, Orange City, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Florida Cancer Specialists, Sarasota, Florida, United States

and more 4 locations

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Phase 1
Recruiting
Conditions
Carcinoma of Unknown Primary
Solid Tumors, Adult
Pancreatic Cancer
Cervical Cancer
Breast Cancer
Non Small Cell Lung Cancer
Endometrial Cancer
Interventions
First Posted Date
2023-06-02
Last Posted Date
2024-08-13
Lead Sponsor
Tango Therapeutics, Inc.
Target Recruit Count
126
Registration Number
NCT05887492
Locations
๐Ÿ‡บ๐Ÿ‡ธ

NEXT Oncology Virginia, Fairfax, Virginia, United States

๐Ÿ‡บ๐Ÿ‡ธ

UCLA Hematology/Oncology, Santa Monica, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Florida Cancer Specialists, Sarasota, Florida, United States

and more 6 locations

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1
Recruiting
Conditions
Locally Advanced Solid Tumor
Interventions
First Posted Date
2023-02-17
Last Posted Date
2024-12-20
Lead Sponsor
Tango Therapeutics, Inc.
Target Recruit Count
225
Registration Number
NCT05732831
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Stanford University, Palo Alto, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sylvester Comprehensive Cancer Center, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

University Chicago Medicine, Chicago, Illinois, United States

and more 17 locations

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Phase 1
Active, not recruiting
Conditions
Locally Advanced Solid Tumor
Interventions
First Posted Date
2022-03-11
Last Posted Date
2024-11-08
Lead Sponsor
Tango Therapeutics, Inc.
Target Recruit Count
192
Registration Number
NCT05275478
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California Los Angeles, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of California San Francisco, San Francisco, California, United States

and more 17 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath